PANBELA THERAPEUTICS, INC.
PANBELA THERAPEUTICS, INC. (SNBP): 3 pipeline candidates · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.3 months
D/E -1.28 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for PANBELA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$142K
Quarterly Burn
$2.1M
Runway
2.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| eflornithine | Phase 2 |
| flynpovi | Phase 3 |
| ivospemin | Phase 3 |
Frequently asked questions
How many drug candidates are in PANBELA THERAPEUTICS, INC.'s pipeline?
PANBELA THERAPEUTICS, INC. (SNBP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PANBELA THERAPEUTICS, INC.'s lead drug candidate?
PANBELA THERAPEUTICS, INC.'s most advanced tracked candidate is eflornithine (Phase 2) for Gastric cancer, Type 1 diabetes, metastatic castration-resistant prostate cancer, NSCLC (STK11 mutation).
What is PANBELA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PANBELA THERAPEUTICS, INC. has approximately 2.3 months of cash runway.
Who is the CEO of PANBELA THERAPEUTICS, INC.?
Jennifer K. Simpson Ph is the chief executive officer of PANBELA THERAPEUTICS, INC. (SNBP).
Get the full picture on PANBELA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.